Publication | Closed Access

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1

Tumor BiologyCdk4/6 InhibitionCyclin D1MedicinePharmacologyRaf Inhibitor Ly3009120Cancer BiologyAnti-cancer AgentTumor SuppressorOncologyCell BiologyCancer Research